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Context:Theroleand importanceofcirculatingsclerostin ispoorlyunderstood.Highbonemass (HBM)
causedbyactivating LRP5mutationshasbeen reported tobeassociatedwith increasedplasma scleros-
tin concentrations; whether the same applies to HBM due to other causes is unknown.
Objective: Our objective was to determine circulating sclerostin concentrations in HBM.
Design and Participants: In this case-control study, 406 HBM index cases were identified by screening
dual-energy x-ray absorptiometry (DXA) databases from 4 United Kingdom centers (n  219 088),
excluding significant osteoarthritis/artifact. Controls comprised unaffected relatives and spouses.
Main measures: Plasma sclerostin; lumbar spine L1, total hip, and total body DXA; and radial and
tibial peripheral quantitative computed tomography (subgroup only) were evaluated.
Results: Sclerostin concentrations were significantly higher in both LRP5 HBM and non-LRP5 HBM
cases comparedwith controls:mean (SD) 130.1 (61.7) and 88.0 (39.3) vs 66.4 (32.3) pmol/L (both P
.001, which persisted after adjustment for a priori confounders). In combined adjusted analyses of
cases and controls, sclerostin concentrations were positively related to all bone parameters found
to be increased in HBM cases (ie, L1, total hip, and total body DXA bone mineral density and
radial/tibial cortical area, cortical bone mineral density, and trabecular density). Although these
relationships were broadly equivalent in HBM cases and controls, there was some evidence that
associations between sclerostin and trabecular phenotypes were stronger in HBM cases, particu-
larly for radial trabecular density (interaction P  .01).
Conclusions:Circulatingplasma sclerostin concentrations are increased in both LRP5 andnon-LRP5
HBM compared with controls. In addition to the general positive relationship between sclerostin
andDXA/peripheral quantitative computed tomographyparameters, genetic factors predisposing
toHBMmay contribute to increased sclerostin levels. (J Clin EndocrinolMetab99: 2897–2907, 2014)
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Sclerostin is an endogenous, osteocyte-derived, solubleinhibitor of canonical Wnt signaling and a potent
inhibitor of osteoblastic bone formation. Despite associ-
ations with a range of factors, its role and importance is
poorly understood. In contrast, protein function and ex-
pressionanalyseshaveadvancedunderstandingof scleros-
tin’s paracrine effects. However, although circulating
sclerostin correlates with bone marrow plasma sclerostin,
the extent to which plasma sclerostin leakage reflects un-
derlying bone biology is unclear (1). Hence, studying
plasma sclerostin in a wide range of bone disorders is de-
sirable. Sclerostin concentrations are known to increase
with age, immobility, weight loss, menopause, type 2 di-
abetes mellitus, and denosumab treatment and are greater
in men than women (2–11). Estrogen replacement, PTH
therapy, and physical activity decrease sclerostin in post-
menopausal women (1, 3, 12), whereas bisphosphonates
have variable effects (7, 13, 14). Oral glucocorticoids de-
crease sclerostin concentrations acutely, potentially
through osteocyte apoptosis (15).
Sclerostin deficiency, occurring in sclerosteosis
(OMIM 269500) and Van Buchem’s disease (OMIM
239100), leads towidespread increased bonemineral den-
sity (BMD) and a characteristic skeletal dysplasia includ-
ing fracture resistance (16–18). Heterozygous carriers
have highbonemass (HBM)and fracture resistance but an
otherwise normal phenotype (19), hence current efforts to
develop sclerostin antibodies as a novel anabolic osteo-
porosis treatment. In rodents, in response to mechanical
loading (mechanotransduction), osteocytic sclerostin se-
cretion is reduced, alleviating inhibition of osteoblast ac-
tivity, increasing bone formation and BMD (20, 21). In
humans, raised sclerostin in response to immobility points
toward a similar effect (8, 9, 11). However, the total
amount of bone may determine plasma sclerostin concen-
trations because, in the general population, sclerostin is
positively related to total-body (TB) BMD, particularly in
older individuals, and inversely related tobone turnover in
men and pre- and postmenopausal women (3, 4, 22). Re-
cently, sclerostin has been positively associated with sev-
eral microarchitectural parameters including trabecular
density, assessed by high-resolution peripheral quantita-
tive computed tomography (pQCT) (23), and cortical vol-
umetric BMD and area, by pQCT (24).
Elevated sclerostin concentrations have also been re-
ported in an HBM family with a T253I mutation in the
Wnt pathway regulator low-density lipoprotein receptor-
relatedprotein5 (LRP5) (25).Although thismay reflect an
effect of the mutation on sclerostin metabolism, associa-
tions between bone mass, microarchitecture, and scleros-
tin may equally be responsible. Consistent with the latter
suggestion, pQCT analysis of a phenotypically similar
HBM population revealed differences in a number of mi-
croarchitectural parameters, previously related to scleros-
tin in the general population, including increased trabec-
ular density and cortical volumetric BMD and area (23,
24, 26). These potential relationshipsmay be complicated
further as sclerostin has also been positively associated
with fat mass (FM) (27), as has HBM (28); hence, scleros-
tin-bone relationships may be confounded by adiposity.
We planned to improve understanding of the relation-
ships between bone and circulating sclerostin by examin-
ing the rare and extreme HBM phenotype. We aimed to
determine whether 1) sclerostin concentrations are ele-
vated inHBM,2) if anyobserveddifferences are explained
byLRP5HBMmutations, and3)anydifferences reflect an
altered relationship between sclerostin and bone param-
eters in HBM individuals, taking into account established
confounding factors.
Subjects and Methods
Participant recruitment
The HBM study is a United Kingdom-based multicenter ob-
servational study of adults with unexplained HBM. At 4 of our
largest study centers, 406 HBM index cases were identified by
screening National Health Service (NHS) dual-energy x-ray ab-
sorptiometry (DXA) databases (n  219 088), excluding scans
with significant osteoarthritis and/or other causes of raisedBMD
(eg, surgical metalwork, Paget’s disease, and metastases). Full
details of DXA database screening and participant recruitment
have previously been reported (29). In brief, HBM was defined
as 1) both L1 Z-score3.2 and total hip Z-score1.2 or 2)
both total hip Z-score 3.2 and L1 Z-score 1.2. The L1
lumbar vertebra was used because, in contrast to lower lumbar
levels, it was not associated with the presence of lumbar spine
osteoarthritis assessed on DXA images (29). Index cases passed
on study invitations to their first-degree relatives and spouses/
partners. Relatives/spouses with HBM in turn passed on invita-
tions to their first-degree relatives/spouses. HBM was defined
among spouses as per index cases and among first-degree rela-
tives as summed L1 Z-score plus total hip Z-score of 3.2,
reflecting an established family history of HBM. Family-based
controls comprised unaffected relatives and spouses. All partic-
ipantswere clinically assessedbyonedoctorusinga standardized
structured history and examination questionnaire, after which
TB DXA scans and (nonfasted) phlebotomy were performed.
None had a history of parathyroid disease.
Subsequently, current and lifetime physical activity (PA) was
measured by a short (10-minute) postal questionnaire (prepaid
reply envelope, sent up to 3 times) that included 1) the short last
7 days self-administered international PA questionnaire (IPAQ
2002, http://www.ipaq.ki.se/ipaq.htm (30, 31) and (ii) a histor-
ical PA questionnaire (32–34). 86.5% completed PA question-
naires: those who did not respond had similar anthropometric
characteristics to those who did (data not shown).
Recruitment ran from September 2008 until April 2010.
Written informed consent was collected for all in line with the
Declaration of Helsinki (35). Participants were excluded if18
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years of age, pregnant, or unable to provide written informed
consent for any reason. This study was approved by the Bath
Multicenter Research Ethics Committee and at each NHS Local
Research Ethics Committee.
Sclerostin and bone turnover markers
Two nonfasted EDTA samples were collected and plasma
separated and frozen within 4 hours to 80°C. Sclerostin con-
centrations were measured using ELISA (BI-20442; Biomedica)
(detection limit 3.6 pmol/L) (standard range 0–80 pmol/L).
Bone formation (procollagen type 1 amino-terminal propeptide
[PINP], and total osteocalcin) and resorption (-C-telopeptides
of type I collagen [CTX]) markers were also measured. All had
inter- and intra-assay coefficients of variation6.0% across the
assay working ranges. Electrochemiluminescence immunoas-
says (Roche Diagnostics) were used to measure plasma concen-
trations of PINP, osteocalcin, andCTX(detection limits 4.0, 0.6,
and 0.01 g/L, respectively).
DXA measurements
DXA scans were performed using either GE Lunar Prodigy
DXA (software version 13.2; GE Healthcare) in Birmingham,
Cambridge, andHull or Hologic Discovery/WDXA (Apex soft-
ware version 3.0; Hologic Inc) in Sheffield. All scans were ac-
quired and analyzed according to each manufacturer’s standard
scanning andpositioning protocols. TBBMDandFMweremea-
sured, together with L1 and total-hip BMD. Known differences
in calibration exist between Hologic and GE for all scan types
(36, 40). For lumbar spine and hip scans, systematic bias was
limited by converting all measures to standardized BMD (38,
39). For TB, systematic differences were limited using cross-cal-
ibration equations for all bone and soft tissue regions of interest
(40). Full details havepreviouslybeen reported, includingquality
control checks andgradingofTB scans formetallic artifacts (28).
Because only 330 (59.5%) of the original multicenter study pop-
ulation (29) had TB DXA scans performed, the principal char-
acteristics of individualswho received aTBDXAscanwere com-
pared with those who did not. No differences were observed in
weight, height, sex, age, or ethnicity (data not shown).
pQCT measurements
At our largest study center, with the necessary equipment,
pQCT scanning was performed at the distal and midshaft of the
tibia (4% and 66% from distal endplate) and radius (4% and
60%) in the nondominant lower and upper limbs, respectively,
using a Stratec XCT2000L (Stratec Medizintechnik) with voxel
size 0.5 mm, CT speed 30 mm/s, and XCT software version
5.50d; details have been previously described in full (26). The
initial frontal scout view determined a distal endplate reference
line. Cortical bone was defined using a threshold650 mg/cm3
(optimal for bone geometry) (41). Trabecular bone was identi-
fied by elimination of cortical bone, and therefore, trabecular
density was defined as650 mg/cm3. Cortical parameters were
measured: cortical BMD, total bone area (BA) (ie, total bone
cross-section, reflecting periosteal expansion), cortical BA (re-
flecting combined periosteal and endosteal expansion). Strength
strain index (SSI) was calculated according to Stratec’s manual:
SSISM (cortical BMD[mg/cm3]/1200mg/cm3),where1200
mg/cm3 represents normal bone physiological density and SM
(section modulus)  CSMI/periosteal radius, where CSMI
(cross-sectional moment of inertia [cm4])  [Pi] (periosteal ra-
dius4  endosteal radius4)/4) (42).
Statistical methods
Descriptive statistics are presented as mean (95% confidence
interval [CI]) for continuous and count (percentages) for cate-
gorical data.Analyses comparing 2 continuous variables are pre-
sented as-coefficients and95%CIs for standardized outcomes.
Linear regression was used to analyze continuous variables, us-
ing random-effects models to allow for the lack of statistical
independence due to within-family clustering of environmental
factors and sharedgenotypes.Age, gender, historical/currentPA,
height, TB FM, menopausal status, and estrogen replacement
therapy inwomen (an established regulator of sclerostin) (12),
were considered a priori confounders of associations between
HBM status and sclerostin, DXA, and bone turnover
parameters.
Further potential confounders included history of malig-
nancy, diabetes mellitus, glucocorticoid (current/previous/never
use), antiresorptive medication use (7, 13–15). Bone density and
microarchitecture analyses were stratified to assess interactions
by HBM case/control status. Data were managed using Mi-
crosoft Access (data entry checks; error rate 0.12%) and an-
alyzed using Stata release 12 statistical software (StataCorp).
Results
Participant characteristics
In total, 202 HBM cases (151 index cases, 49 affected
relatives, and 2 affected spouses) and 123 family controls
(87 unaffected relatives and 36 unaffected spouses) were
assessed. HBM cases (age range 26–90 years) were older
than family controls (19–88 years) and more commonly
female, postmenopausal, and had used estrogen replace-
ment (Table 1). Only 4 HBM cases were not of white
European origin.
Plasma sclerostin concentrations
As expected, sclerostin concentrations were strongly
associated with age in both HBM cases (unadjusted stan-
dardized  per year increase in age 0.03 [0.02, 0.04], P
.001) and controls (0.02 [0.01, 0.03], P .001) to a sim-
ilar degree (interactionP .48). Sclerostin concentrations
(mean [SD]) were higher in males than females in both
HBMcases (112.5 [46.8] vs 80.9 [33.7] pmol/L,P .001)
and controls (72.8 [37.2] vs 58.6 [23.1] pmol/L,P .042),
without evidence of interaction. Sclerostin concentrations
were independent of bone turnover markers (overall and
in men, women, HBM cases, and controls) and TB FM
(data not shown).
Unadjusted sclerostin concentrations were signifi-
cantly higher among HBM cases compared with controls
(Table 2). These differences were maintained after adjust-
ment for a priori confounders, ie, age, gender, historical/
current PA, height, TB FM, and in women years since
doi: 10.1210/jc.2013-3958 jcem.endojournals.org 2899
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 August 2014. at 01:41 For personal use only. No other uses without permission. . All rights reserved.
menopause and estrogen replacement therapy. Addi-
tional adjustment for diabetes mellitus, malignancy,
and glucocorticoid and antiresorptive use did not in-
fluence these findings (Supplemental Table 1, published
on The Endocrine Society’s Journals Online website at
http://jcem.endojournals.org).
To determine the impact of rare cases of HBM caused
by anabolic mutations in LRP5, identified by previous
Sanger sequencing (43), we first assessed sclerostin con-
centrations in 6 cases ofLRP5HBMand second in the 196
non-LRP5 HBM cases. Sclerostin concentrations were
highest among the 6 LRP5HBM cases (mean [SD], 130.1
[62.7] pmol/L) (Figure 1) but were also elevated in non-
LRP5 HBM cases compared with controls (unadjusted
mean difference 22.1 [13.3, 30.9] pmol/L, P .001) (Fig-
ure 1). Adjustment for a priori confounders did not di-
minish the difference in sclerostin concentrations ob-
served between non-LRP5 HBM cases and controls
(Figure1).Theapriori adjustedmeandifference in scleros-
tin levels between LRP5 and non-LRP5 HBM cases was
halved by further adjustment for TB BMD (mean differ-
ence, 35.2 [0.92, 71.3] pmol/L, P  .056).
Sclerostin and DXA-measured BMD
As previously reported (29), BMD was considerably
higher in HBM individuals than controls in unadjusted
analyses and persisted after adjustment for a priori and
additional confounders (Table 2 and Supplemental Table
1). To establish whether sclerostin differences could be
explained by variation in BMD, we first investigated the
relationship between DXA BMD and sclerostin in our
combined study population. Before adjustment, strong
positive relationships were seen between BMD and
sclerostin ( represents SD change in sclerostin per SD
increase in BMD) measured at L1 (0.32 [0.22, 0.43]), the
total hip (0.25 [0.15, 0.35]) and TB (0.26 [0.16, 0.37])
(P .001 for all). Equivalent relationships were observed
after adjustment for a priori confounders (Table 3) and
additional confounders (SupplementalTable 2). In further
analyses, intended to examine whether BMD-sclerostin
relationships differed according to HBM case status, as-
sociations were generally stronger between DXA BMD
parameters and sclerostin in HBM cases, as judged by
-coefficients, especially for L1 BMD; however, despite
this, no formal HBM case-control interactions were de-
tected (all P  .05) (Table 3).
Sclerostin and bone microarchitecture measured
by pQCT
The positive relationships observed between DXA-
measured BMD and sclerostin were next investigated us-
Table 1. Clinical Characteristics of HBM Cases and Family Controlsa
HBM Cases
(n  202)
Controls
(n  123)
P
Valueb
Mean (SD)
Age, y 61.4 (13.6) 55.2 (16.3) .001
Height, cm 166.6 (9.2) 171.6 (10.6) .001
Weight, kg 85.3 (17.4) 84.0 (17.4) .784
BMI, kg/m2 30.7 (5.8) 28.4 (5.0) .001
TB LM, kg 46.8 (10.2) 51.5 (11.3) .001
TB FM, kg 35.7 (12.5) 30.0 (11.3) .001
n (%)
Female 153 (76.5) 55 (44.7) .001
Postmenopausal 127 (83.0) 29 (52.7) .001
Estrogen replacement use (ever) 77 (53.1) 9 (18.4) .001
Previous fracture (ever) 75 (37.5) 61 (49.6) .033
Diabetes mellitus 20 (10.0) 10 (8.1) .574
Current/previous glucocorticoid use 49 (24.5) 19 (15.5) .053
Malignancy (ever) 31 (15.5) 7 (5.7) .008
Current PA (IPAQ) (n  290)
Low 28 (15.4) 14 (13.0)
Moderate 71 (39.0) 41 (38.0) .791
High 83 (45.6) 53 (49.1)
Historical PA score (n  288)
Very low (0–4) 21 (11.7) 13 (12.0)
Low (5–7) 34 (18.9) 27 (25.0)
Moderate (8–10) 37 (20.6) 26 (24.1) .369
High (11–14) 45 (25.0) 17 (15.7)
Very high (15–24) 43 (23.9) 25 (23.2)
Abbreviations: BMI, body mass index; IPAQ, International Physical Activity Questionnaire; LM, lean mass.
a No individuals had hypercalcemia.
b Unadjusted P value from regression model accounting for within-family clustering. Only 9 HBM cases and 2 controls had ever used antiresorptive
medication.
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ing lower and upper limb pQCT available in 95 HBM
cases and65 controls (4 tibial pQCT images discardeddue
tomovement artifact).When the clinical characteristics of
individuals undergoing pQCT assessment were compared
with those who did not, no differences were observed in
gender, age, weight, height, physical activity, menopausal
status, or estrogen replacement use (data not shown). Be-
fore adjustment, trabecular density was markedly greater
at both the tibia and radius in HBM cases compared with
controls, as were cortical density and thickness, albeit to
a lesser extent (Table 2). After adjustment for a priori
confounders, trabecular density, cortical density, cortical
BA, and SSI, at both the tibia and radius,were all observed
to be greater in HBM cases compared with controls; how-
ever, bone sizes (total BA) were similar (Table 2). Equiv-
alent resultswere obtained after adjustment for additional
confounders (Supplemental Table 1).
Using our regression model adjusted for a priori con-
founders, we assessed the strength of relationships be-
tween SD changes in our pQCT measures of bone micro-
architecture and sclerostin (standardized). In the study
population as a whole, at both the radius and tibia, strong
positive relationships were seen between trabecular den-
sity, cortical density, cortical BA, and sclerostin; a rela-
tionship with SSI was seen only at the radius. Sclerostin
was independent of bone size (total BA) in both upper and
lower limbs (Table 3). These relationships were un-
changed by further adjustment for PINP, plasma CTX,
and osteocalcin (data not shown) or by further potential
confounders (diabetes mellitus, malignancy, and gluco-
corticoid and antiresorptive use) (Supplemental Table 2).
In stratified analyses, few consistent differences were ob-
served in the relationships between pQCTparameters and
sclerostin inHBMcases and controls. Themain exception
was the association between trabecular density and
sclerostin, which was stronger in HBM cases compared
with controls at both the radius and tibia, with a formal
interaction by case status observed in the upper limb (Ta-
ble 3 and Figure 2).
Sensitivity analyses
Relationshipsbetweenmeasured (DXAandpQCT)bone
parameters and sclerostin were not materially altered after
exclusion of LRP5HBM cases (Supplemental Tables 3–7).
Discussion
This study is the first to measure circulating sclerostin
concentrations ina largepopulationwithHBM.We found
Table 2. DXA and pQCT Measurements in HBM Cases Compared With Family Controlsa
HBM Mean
(SD)
Control
Mean (SD)
Unadjusted Mean
Difference (95%CI)
Unadjusted
P Value
Adjusted Mean
Differenceb (95% CI)
Adjusted P
Valueb
Sclerostin,c pmol/L 89.6 (40.7)d 66.4 (32.3) 21.9 (13.6, 30.1) .001 23.5 (14.5, 32.4) .001
DXA (n  323)
L1 sBMD, g/cm2 1.40 (0.16) 1.08 (0.16) 0.32 (0.29, 0.36) .001 0.35 (0.32, 0.39) .001
Total Hip sBMD,
g/cm2
1.25 (0.18) 0.99 (0.14) 0.25 (0.21, 0.28) .001 0.29 (0.25, 0.32) .001
TB BMD,e g/cm2 1.34 (0.13) 1.22 (0.12) 0.11 (0.09, 0.14) .001 0.16 (0.13, 0.18) .001
Tibia pQCT (n  156)
Total BA, mm2 633.5 (98.4) 653.3 (111.0) 20.3 (53.4, 12.8) .229 21.5 (7.33, 50.3) .144
cBMD, mg/cm3 1127.7 (33.2) 1111.4 (51.9) 16.2 (2.85, 29.6) .017 18.5 (3.44, 33.6) .016
Cortical BA, mm2 337.6 (55.3) 325.2 (67.6) 12.4 (6.95, 31.7) .209 33.4 (20.3, 46.4) .001
SSI, mm3 1651.0 (363.1) 1636.3 (435.7) 14.8 (111.1, 140.6) .818 191.7 (110.7, 272.7) .001
tBMD, mg/cm3 315.2 (34.0) 276.6 (38.5) 38.6 (27.3, 50.0) .001 40.5 (28.8, 52.3) .001
Radius pQCT (n 160)
Total BA, mm2 161.1 (32.5) 161.8 (29.7) 1.1 (10.8, 8.57) .823 7.63 (1.43, 16.7) .099
cBMD, mg/cm3 1170.0 (38.1) 1151.2 (60.4) 18.8 (3.52, 34.0) .016 27.1 (10.8, 43.5) .001
Cortical BA, mm2 99.8 (16.7) 96.7 (20.4) 3.10 (2.68, 8.88) .293 12.1 (7.32, 16.8) .001
SSI, mm3 241.1 (63.3) 233.7 (65.9) 7.43 (12.9, 27.7) .473 34.7 (17.6, 51.8) .001
tBMD, mg/cm3 286.9 (34.5) 264.0 (33.9) 22.9 (12.2, 33.7) .001 26.7 (14.7, 38.6) .001
Abbreviation: cBMD, cortical BMD; sBMD, standardized BMD; tBMD, trabecular BMD; BA, bone area.
a HBM cases are excluding LRP5 HBM. All pQCT measures were taken from the 66% and 60% slices for tibia and radius, respectively, except for
trabecular density measured at the 4% slice.
b Adjusted for age, gender, historical and current PA, height, TB FM, and years since menopause and estrogen replacement therapy in women,
with P values from regression accounting for within-family clustering.
c Standard range 0–80 pmol/L. Unadjusted median [IQR] for HBM cases and controls: 81.1 [61.6, 103] and 60.4 [43.7, 86] pmol/L, respectively).
d There were145 HBM cases with L1 Z-score 3.2 and mean (SD) sclerostin of 91.1 (40.7) pmol/L; 87 HBM cases with total hip Z-score 3.2
with sclerostin 94.4 (38.2) pmol/L; and 65 HBM cases with both L1 Z-score 3.2 and total hip Z-score 3.2 with sclerostin level of 95.2 (41.6)
pmol/L.
e Adjusted for metallic artifact.
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HBM cases, identified by screening routine NHS DXA
databases across the United Kingdom, to have substan-
tially increased sclerostin concentrations in comparison
with their unaffected family members. Sclerostin concen-
trations inmost of ourLRP5HBMcases, previously iden-
tified by capillary sequencing of exons 2, 3, and 4 (43),
were higher comparednot onlywith controls but alsowith
the remainder of the HBM population. Our findings are
consistent with the one LRP5 HBM family pedigree in
which sclerostin has been measured; although the specific
mutation differed from ours, average sclerostin concen-
trations were almost double that of controls, just as we
observed (25). Even after excluding individuals with
LRP5 mutations, sclerostin concentrations were signifi-
cantly higher in our HBM cases than among controls, a
difference unchanged by adjustment for factors we con-
firmed influence sclerostin concentrations, suchas age and
gender.
The higher sclerostin concentrations among our HBM
cases are likely to be, at least partly, explained by the
positive relationship between sclerostin and BMD. This
relationship, previously reported in population-based
studies of lumbar and total hip BMD (4, 13, 22), was also
seen here at L1, total hip, and TB BMD among pooled
HBM cases and controls. This may reflect an association
between sclerostin and total osteocyte number, given that
osteocytes are a major source of sclerostin (44, 45), and
BMD reflects the amount of bone tissue and hence osteo-
cyte number. Our microarchitectural analyses support el-
evated sclerostin concentrations reflecting a greater quan-
tity of bone tissue in HBM cases. As previously reported
(26), pQCT analyses revealed HBM cases to have greater
cortical and trabecular bone, demonstrated by increased
cortical area and trabecular density, respectively, both of
which showed positive associations with sclerostin in
pooled analyses of HBM cases and controls. These find-
ings concur with recent population-based analyses in
which sclerostin has been positively related to cortical
bone area and trabecular density in older women (24) and
cortical thickness and trabeculardensity inadultmen (23).
We identified a positive relationship between sclerostin
and cortical BMD, as observed in population-based stud-
ies (23, 24); this may contribute to the increased sclerostin
in HBM cases, because cortical BMD is also raised in
HBM.Dense cortical bone,with fewer remodeling spaces,
may consequently harbor more osteocytes, resulting in
greater sclerostin production. However, greater cortical
BMDmay result in greater measured cortical thickness by
reducing the impact of partial volume effects that other-
wise limit edge detection accuracy in the presence of low
cortical BMD. Alternatively, because cortical BMD is in-
versely related to bone remodeling and turnover, the pos-
itive relationship between sclerostin and cortical BMD,
whichwe and others have observed,may reflect an inverse
association between bone turnover and plasma sclerostin.
Such a relationship has previously been suggested in post-
menopausal women and older men (3, 22), although po-
tentially not for osteocalcin (12), although in the present
study, no association was observed between sclerostin
concentrations and bone turnover, despite the validity of
our sclerostin assay (46). The clinical utility of sclerostin
measurement remains to be determined.
Although sclerostin concentrations were elevated in
HBM cases both with and without LRP5mutations, they
werehighest inmostwithLRP5mutations comparedwith
other HBM cases. This may reflect a more extreme phe-
notype in LRP5HBM, with greater amounts of bone tis-
sue (reflected by greater trabecular and cortical bone vol-
umes) (26) and hence osteocyte number, than occurs in
non-LRP5 HBM cases. Consistent with this suggestion,
LRP5 HBM cases had greater BMD compared with the
remainder of the HBM population (our unpublished ob-
servations); LRP5 HBM mouse models exhibit reduced
osteocyte apoptosis (47). Alternatively, individuals with
LRP5mutationsmay produce greater amounts of scleros-
tin for a given quantity of bone tissue comparedwith non-
LRP5 HBM cases. Although the small numbers of LRP5
Figure 1. Plasma sclerostin concentrations in HBM cases with and
without LRP5 anabolic mutations and controls. LRP5 HBM cases n  6;
non-LRP5 HBM cases n  196; and controls n  123. **, P  .001.
Unadjusted mean difference between LRP5 HBM cases and controls 
63.4 [35.4, 91.5]**, between non-LRP5 HBM cases and controls 
22.1 [13.3, 30.9]**, and between LRP5 HBM cases and non-LRP5 HBM
cases  42.0 [9.32, 74.8], P  .012. Mean differences in sclerostin are
shown with 95% CIs after adjustment for a priori confounders (age,
gender, historical and current PA, height, TB FM, and years since
menopause and estrogen replacement therapy in women). The
unadjusted data points for the 6 LRP5 HBM cases are superimposed in
gray rectangles.
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Table 3. Adjusted Regression Coefficients for Associations Between Sclerostin and Standardized Bone Parametersa
 (95% CI)b P Valueb P Valuec
DXA BMD (n  320)
L1 sBMD, g/cm2
All .290 (.185, .395) .001 .167
HBM .313 (.087, .539) .007
Controls .051 (.129, .231) .580
Total hip sBMD, g/cm2
All .339 (.203, .448) .001 .402
HBM .341 (.129, .554) .002
Controls .127 (.104, .358) .283
TB BMD,d g/cm2
All .344 (.223, .465) .001 .464
HBM .310 (.093, .528) .005
Controls .156 (.044, .356) .126
Tibia pQCT (n  156)
Total BA, mm2
All .029 (.214, .272) .818 .213
HBM .042 (.323, .408) .821
Controls .180 (.510, .150) .286
Cortical BMD, mg/cm3
All .182 (.018, .346) .029 .191
HBM .061 (.222, .344) .673
Controls .291 (.083, .499) .006
Cortical BA, mm2
All .451 (.171, .730) .002 .325
HBM .268 (.208, .744) .270
Controls .526 (.107, .944) .014
SSI, mm3
All .323 (.043, .602) .024 .367
HBM .172 (.295, .638) .471
Controls .232 (.195, .659) .287
Trabecular BMD, mg/cm3
All .307 (.147, .468) .001 .301
HBM .298 (.032, .564) .028
Controls .113 (.163, .388) .422
Radius pQCT (n  160)
Total BA, mm2
All .060 (.224, .104) .476 .140
HBM .081 (.305, .143) .478
Controls .098 (.359, .163) .462
Cortical BMD, mg/cm3
All .252 (.101, .402) .001 .699
HBM .239 (.027, .504) .078
Controls .106 (.098, .310) .309
Cortical BA, mm2
All .254 (.067, .441) .008 .363
HBM .147 (.156, .449) .342
Controls .170 (.093, .432) .204
SSI, mm3
All .119 (.067, .305) .211 .303
HBM .043 (.229, .315) .756
Controls .037 (.245, .318) .799
Trabecular BMD, mg/cm3
All .382 (.228, .537) .001 .009
HBM .499 (.264, .735) .001
Controls .137 (.068, .342) .190
Abbreviation: sBMD, standardized BMD.
a HBM cases are excluding LRP5 HBM. All pQCT measures were taken from the 66% and 60% slices for tibia and radius, respectively, except for
trabecular density measured at the 4% slice (95 HBM cases and 65 controls). The -values represent SD change in sclerostin per SD increase in
BMD/bone parameter.
b Adjusted for age, gender, historical and current PA, height, TB FM, and years since menopause and estrogen replacement therapy in women.
c Interaction P value.
d Adjusted for metal artifact.
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HBMcases limitedourability to examine thisquestion,we
found some evidence that HBM cases overall produce rel-
atively large amounts of sclerostin per unit of bone tissue,
as reflected by the stronger relationship particularly be-
tween radial trabecular density and sclerostin concen-
trations in HBM cases, than was seen in controls. If
HBM cases have predisposing genetic factors toward
greater BMD and greater sclerostin concentrations,
these effects may be exaggerated in those harboring
LRP5 mutations. For example, rare monogenic LRP5
HBM cases are likely to have mutations conveying a
relatively strong functional effect comparedwith that of
common polymorphisms affecting BMD. Polymor-
phisms in established BMD genes are known to be over-
represented among individuals with HBM (48–50),
suggesting common polymorphisms, each individually
exerting relatively weak effects, contribute to the ex-
treme bone phenotype in our non-LRP5 HBM cases.
Any tendency for sclerostin production to be preferen-
tially increased in LRP5 HBM may reflect which molec-
ular pathways have been perturbed. LRP5, a cell surface
coreceptor regulating canonical Wnt signaling, plays a
central role in osteoblast differentiation (51). Anabolic
LRP5 mutations disrupt binding of endogenous Wnt in-
hibitors such as dickkopf1, prompting activation of
downstream signaling and gene transcription via
-catenin. Expression of sclerostin, which also functions
as an endogenous inhibitor of Wnt signaling, may con-
ceivably be increased in this context of dysregulated acti-
vationofWnt signaling. Potentially, a subset of non-LRP5
HBM cases may also arise from genetic perturbations af-
fecting Wnt signaling, which might contribute to the in-
creased sclerostin concentrations observed in our analy-
ses. Interestingly, of the common polymorphisms
associated with BMD in large-scale genome-wide associ-
ation studies, gene ontology links several to roles in os-
teoblastic Wnt signaling (49, 52); as discussed above,
polymorphisms in these BMD-associated loci occur more
frequently in our HBM population.
Importantly, sclerostin is not osteocyte-specific; a
range of isoforms have been localized in osteoblasts, os-
teoclasts, and chondrocytes (53). In rodent models,
sclerostin is strongly expressed in ossified ligaments and
osteophytes emerging by endochondral ossification (37).
HBM has been associated with both ligament ossification
and increased prevalence of joint replacement (potentially
due to osteoarthritis) (29, 54) and, more recently, genetic
Figure 2. Plasma sclerostin concentrations vs trabecular density measured by pQCT at the distal radius and tibia. HBM represents HBM cases not
explained by LRP5 mutations (F), and FC represents family controls (gray triangles).  represents SD change in sclerostin per SD increase in
trabecular density, with 95% CI shown. a, Adjusted for age, gender, historical and current PA, height, TB FM, and years since menopause and
estrogen replacement therapy in women.
2904 Gregson et al Elevated Sclerostin in High Bone Mass J Clin Endocrinol Metab, August 2014, 99(8):2897–2907
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 11 August 2014. at 01:41 For personal use only. No other uses without permission. . All rights reserved.
markers forMEF2C and SOX6,which both have regula-
tory roles in endochondral ossification (48, 49).
Limitations
One potential limitation concerns control individuals
comprising relatives/spouses rather than being drawn
from the general population. These were considered suit-
able because 1) they had appropriate BMD (Table 1), 2)
they share common environmental factors with cases that
would otherwise be difficult tomeasure and control for as
confounding factors, and 3) their inclusion aids future
genetic analyses as trait-associated haplotypes can be
readily identified. However, family controls are likely to
have beenmore similar toHBMcases than unrelated pop-
ulation controls; hence, clustered analyses were per-
formed to account for the lack of statistical independence
due to within-family clustering of environmental factors
and shared genotypes. Despite this, our reported differ-
ences may still underestimate the true magnitude of the
HBM phenotype than had HBM cases been compared
with general population controls. We were able to adjust
for differences between cases and controls in gender, post-
menopausal status, estrogen replacement, glucocorticoid
use, and prior history ofmalignancy,which reflect referral
indications for clinical DXA services (29). However, we
cannot exclude residual confounding, for example, by
PTHor renal function;measurementswe lacked.Reduced
sample size limited analysis of pQCT measurements that
were available in only 50%; however, these individuals
were representative of the whole study population.
Conclusions
Our case-control study found plasma sclerostin con-
centrations to be increased in HBM cases compared with
family controls. These increases were particularly marked
inHBMcases withLRP5mutations, although cases with-
out LRP5 mutations also had higher sclerostin concen-
trations comparedwith controls. Sclerostinwas positively
related to BMD, measured by DXA, and to trabecular
density and cortical area,measured by pQCT, all ofwhich
weremeasures found also to be increased inHBM.Hence,
sclerostin concentrationsmaybe increased inHBMinpart
due to a greater osteocyte number resulting from greater
quantities of trabecular and cortical bone tissue. In addi-
tion, greater production of sclerostin per unit of bone tis-
suemaycontribute to thesedifferences, as suggestedby the
stronger relationship between sclerostin concentrations
and trabecular density in HBM cases compared with con-
trols. Further analyses of relationships between sclerostin
and genetic factors predisposing to HBM is justified to
shed new light on the mechanisms regulating sclerostin
production.
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